Anastasios Stathis

8.0k total citations · 4 hit papers
198 papers, 4.9k citations indexed

About

Anastasios Stathis is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Anastasios Stathis has authored 198 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 85 papers in Molecular Biology and 85 papers in Pathology and Forensic Medicine. Recurrent topics in Anastasios Stathis's work include Lymphoma Diagnosis and Treatment (84 papers), Chronic Lymphocytic Leukemia Research (47 papers) and Protein Degradation and Inhibitors (40 papers). Anastasios Stathis is often cited by papers focused on Lymphoma Diagnosis and Treatment (84 papers), Chronic Lymphocytic Leukemia Research (47 papers) and Protein Degradation and Inhibitors (40 papers). Anastasios Stathis collaborates with scholars based in Switzerland, Italy and United States. Anastasios Stathis's co-authors include Malcolm J. Moore, Francesco Bertoni, Emanuele Zucca, Franco Cavalli, Mohamed Békradda, Keyvan Rezaï, Jean‐Pierre Delord, Luciano Cascione, Chiara Tarantelli and Eugenio Gaudio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anastasios Stathis

189 papers receiving 4.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advanced pancreatic carcinoma: current treatment and future challenges

2010 641 citations Anastasios Stathis et al. profile →
BET Proteins as Targets for Anticancer Treatment

2017 343 citations Anastasios Stathis, Francesco Bertoni Cancer Discovery profile →
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Anastasios Stathis, Patrice Herait et al. profile →
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Anastasios Stathis	2.6k	2.0k	1.4k	883	571	198	4.9k
Martin Gutierrez	1.7k 0.7×	2.3k 1.1×	1.1k 0.8×	387 0.4×	772 1.4×	205	4.5k
Raoul Tibes	3.6k 1.4×	1.5k 0.7×	578 0.4×	1.4k 1.6×	418 0.7×	144	5.3k
Thomas Pabst	1.6k 0.6×	1.2k 0.6×	738 0.5×	2.5k 2.8×	307 0.5×	180	4.3k
J Garcı́a-Conde	954 0.4×	2.0k 1.0×	1.1k 0.8×	984 1.1×	425 0.7×	104	3.9k
Frank Griesinger	1.5k 0.6×	1.7k 0.8×	773 0.5×	1.7k 1.9×	1.7k 3.0×	275	5.1k
Elizabeth A. Punnoose	1.9k 0.7×	1.6k 0.8×	921 0.7×	868 1.0×	677 1.2×	52	3.9k
Cyrus V. Hedvat	2.6k 1.0×	1.7k 0.9×	530 0.4×	1.3k 1.5×	597 1.0×	76	5.4k
Yasuhiro Oki	2.2k 0.8×	2.3k 1.2×	3.1k 2.2×	1.3k 1.5×	440 0.8×	207	6.3k
Alejandro D. Ricart	1.4k 0.5×	2.5k 1.2×	1.0k 0.7×	212 0.2×	762 1.3×	57	4.0k
Mark Roschewski	779 0.3×	1.3k 0.7×	1.4k 1.0×	485 0.5×	229 0.4×	131	2.9k

Countries citing papers authored by Anastasios Stathis

Since Specialization

Citations

This map shows the geographic impact of Anastasios Stathis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anastasios Stathis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anastasios Stathis more than expected).

Fields of papers citing papers by Anastasios Stathis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anastasios Stathis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anastasios Stathis. The network helps show where Anastasios Stathis may publish in the future.

Co-authorship network of co-authors of Anastasios Stathis

This figure shows the co-authorship network connecting the top 25 collaborators of Anastasios Stathis. A scholar is included among the top collaborators of Anastasios Stathis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anastasios Stathis. Anastasios Stathis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spriano, Filippo, Chiara Tarantelli, Eugenio Gaudio, et al.. (2024). Targeting CD25 + lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. British Journal of Haematology. 205(5). 1873–1882. 2 indexed citations

Colombo, Ilaria, Simon Haefliger, Manuela Rabaglio, et al.. (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European Journal of Cancer. 201. 113588–113588. 10 indexed citations

Pirosa, Maria Cristina, Anastasios Stathis, & Emanuele Zucca. (2024). Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma. Human Vaccines & Immunotherapeutics. 20(1). 2309701–2309701. 5 indexed citations

Papadopoulos, Kyriakos P., Manish Sharma, Reinhard Dummer, et al.. (2024). Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.. Journal of Clinical Oncology. 42(16_suppl). 3120–3120. 5 indexed citations

Motta, Lucia, et al.. (2024). Antibody-drug conjugates combinations in cancer treatment. SHILAP Revista de lepidopterología. 5(3). 714–741. 4 indexed citations

Espeli, Vittoria, Antonio Gómez, Panagiotis Balermpas, Giorgio Treglia, & Anastasios Stathis. (2024). A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer. SHILAP Revista de lepidopterología. 11. 100588–100588. 1 indexed citations

Sartori, Giulio, Chiara Tarantelli, Filippo Spriano, et al.. (2023). The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib. British Journal of Haematology. 204(1). 191–205. 7 indexed citations

Stathis, Anastasios, Anthony W. Tolcher, Daniel J. Renouf, et al.. (2023). Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors. Investigational New Drugs. 41(3). 380–390. 11 indexed citations

Hamadani, Mehdi, Alexander I. Spira, Xiaolei Zhou, et al.. (2023). Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Advances. 8(1). 93–98. 5 indexed citations

10.

Alderuccio, Juan Pablo, Weiyun Z. Ai, John Radford, et al.. (2022). Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Advances. 6(16). 4736–4739. 1 indexed citations

11.

Colombo, Ilaria, Sofia Genta, Federica Martorana, et al.. (2021). Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research. 27(18). 5012–5019. 27 indexed citations

12.

Martorana, Federica, Ilaria Colombo, Giorgio Treglia, Silke Gillessen, & Anastasios Stathis. (2021). A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. Cancer Treatment Reviews. 101. 102300–102300. 10 indexed citations

13.

Mensah, Afua A., Filippo Spriano, Giulio Sartori, et al.. (2021). Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Advances. 5(10). 2467–2480. 12 indexed citations

14.

Mestre, Ricardo Pereira, Giorgio Treglia, Matteo Ferrari, et al.. (2018). Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis. European Journal of Clinical Investigation. 49(3). e13063–e13063. 34 indexed citations

15.

Ceriani, Luca, Lisa Milan, Maurizio Martelli, et al.. (2018). Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 132(2). 179–186. 72 indexed citations

16.

Stathis, Anastasios, Emanuele Zucca, Mohamed Békradda, et al.. (2016). Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discovery. 6(5). 492–500. 268 indexed citations

17.

Paone, Gaetano, et al.. (2016). Limited Benefit of Additional Contrast-Enhanced CT to End-of- Treatment PET-CT Evaluation in Patients with Follicular Lymphoma. Blood. 128(22). 5925–5925. 1 indexed citations

18.

Boi, Michela, Eugenio Gaudio, Paola Bonetti, et al.. (2015). The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical Cancer Research. 21(7). 1628–1638. 214 indexed citations

19.

Bédard, Philippe L., Josep Tabernero, Filip Jankú, et al.. (2014). A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research. 21(4). 730–738. 257 indexed citations

20.

Stathis, Anastasios, Sébastien J. Hotte, Eric X. Chen, et al.. (2011). Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. Clinical Cancer Research. 17(6). 1582–1590. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact